The use of yeasts enables an ideal combination of hardy growth on simple media in large-scale bioreactors with the capacity of the desired post-translational modifications and feasibility in genetic manipulations (Mattanovich , make them practical alternative hosts for biotechnological purposes.
The biopharmaceutical products produced in various yeast species, which are on the market or in the final stages of development, are summarized in Table 2.
Yeast cells are particularly advantageous as hosts for biopharmaceutical production in that they are generally recognized as safe (GRAS) organisms.
These tools can target different levels in biosynthetic processes and allow multilevel modifications of yeast host strains to improve the quality and yield of recombinant proteins.
Efficient transcription is a critical step in controlling gene expression at the initial stage.
In this review, we address recent advances in yeast synthetic biology with respect to therapeutic recombinant protein production, particularly focusing on genetic tools and host strains suitable for secretory protein production in several yeast expression systems.
Pharmaceutical proteins comprise one of the fastest growing groups of molecular medicines and currently play important roles in the treatment of many diseases.